WVE — Wave Life Sciences Ltd.
$3.18-5.07%
Last close: · regular session
Last 60 sessions
WVE closed at $3.18 (-5.07%) on Oct 23, 2026. Float: 150.5M shares. Latest SEC filing: ARS on Oct 14, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for WVE in the TickerWise workspace.
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: SG
- Exchange: NASDAQ
- Employees: 287
- Website: https://www.wavelifesciences.com
Latest SEC filings for WVE
Latest WVE news
- Wave Life Sciences Q3 2026 Earnings Preview Read article
- Wave Life Sciences to Present at Chardan's 10th Annual Healthcare Conference Read article
- WAVE Life Sciences (NASDAQ:WVE) Shares Climb 9.3% – Here’s What Happened Read article
- Wave Life jumps as FDA backs registrational plans for AATD therapy Read article
- Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD Read article
- Wave to receive $12M milestone as GSK picks liver candidate Read article
- Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development Read article
- 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.